Videos

The experts describe a new drug under review by the FDA that offers an option for patients with MPNs and low platelets and discuss what they are looking forward to in the next 3-5 years.

The doctors discuss withdrawing patients with MPNs from a JAK inhibitor, titration, and rechallenging.

An expert in the treatment of HCC comments on first-line therapeutic options for patients with previously untreated, advanced HCC.

Combination trials and new agents for MPNs, such as parsaclisib and momelotinib, are discussed in the context of recent ASCO presentations.

Dr Gholam, MD, provides expert analysis on the prognosis and treatment of a patient with unresectable HCC.

Alternative dosing schedules and the use of JAK inhibitors for patients with MPNs in the second-line setting are explored.

Pierre Gholam, MD, presents the case of a 61-year-old woman with hepatocellular carcinoma (HCC).

Samantha E. Greenberg, MS, MPH, CGC, discusses if the changes to the National Comprehensive Cancer Network’s Clinical Practice Guidelines for Prostate Cancer. NCCN has expanded germline testing in metastatic prostate cancer to all patients with high-risk, very high-risk, or regional prostate cancer.

The relationship between germline mutations in DNA repair genes and advanced urothelial carcinoma, and tips for counseling patients who are candidates for germline testing.

Disease characteristics and risk factors associated with urothelial carcinoma that create a significant burden for patients, loved ones, and health care professionals across the globe.

Travis Sims, MD, MPH, discusses the impact of homologous recombination deficiency status of clinical and survival outcomes in patients with advanced-stage ovarian cancer.

Peter A. Riedell, MD, discusses the clinical implication of using frontline high-dose rituximab-based therapy and autologous hematopoietic cell transplantation in patients with mantle cell lymphoma in an analysis of time to relapse.

Laurie Sehn, MD, discusses the unmet needs and future directions in the treatment of relapsed/refractory diffuse large B-cell lymphoma.

A key opinion leader reviews novel therapies for diffuse large B-cell lymphoma.

Dr Laurie Sehn reviews the NCCN guidelines for second-line therapy in relapsed/refractory diffuse large B-cell lymphoma and discusses the clinical trial data for a recently approved new treatment combination.

An expert hematologist-oncologist describes risk assessment for diffuse large B-cell lymphoma, as well as first-line therapy selection based on risk and other factors.

Laurie Sehn, MD, presents the case of a 76-year-old man with relapsed/refractory diffuse large B-cell lymphoma.

Nathan Pennell, MD, PhD, discusses the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer.

Neeraj Agarwal, MD, discusses the health-related quality of life and patient-reported outcomes in the TITAN trial of apalutamide versus placebo patients with metastatic castration-sensitive prostate cancer.

Debu Tripathy, MD, discusses the use of tucatinib, capecitabine, and trastuzumab for the treatment of patients with HER2-positive breast cancer and leptomeningeal disease in other HER2-positive cancer types.

Dr Yi-Bin Chen shares his thoughts on future directions and unmet needs in treatment of steroid-refractory GVHD.

Key opinion leader, Yi-Bin Chen, MD, summarizes the clinical trial data supporting the recent FDA approval of ruxolitinib for the treatment of steroid-refractory acute GVHD and provides insights on a potential future role for ruxolitinib in steroid-refractory chronic GVHD.

Dr Yi-Bin Chen reviews treatment options for patients with steroid-refractory chronic GVHD.

Yi-Bin Chen, MD, discusses several approaches to the treatment of steroid-refractory acute GVHD, along with the immunologic pathways they target.

An expert in bone marrow transplantation outlines the main therapy used in the front-line setting to treat GVHD and then provides several definitions of what it means to be steroid-refractory.

Dr Yi-Bin Chen describes several prophylactic regimens commonly used to prevent GVHD following allogeneic hematopoietic stem cell transplant.

Yi-Bin Chen, MD, delineates between acute and chronic GVHD and provides the incidence and risk factors associated with these diseases.

Response criteria, quality of life issues, and therapeutic options including ruxolitinib, hydroxyurea, and interferon are discussed in the context of ET.

Additional treatment options for low- and high-risk patients with MPNs are discussed.

Efficacy and safety profiles of therapies for PV are discussed, along with results of the RESPONSE and RESPONSE-2 studies.